☆ 4.7 Article

Access to High-Cost Biological Agents: Perceptions of Brazilian Patients with Inflammatory Bowel Diseases

JOURNAL OF CLINICAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study

George Khoudari et al.

Summary: In this study, it was found that inflammatory bowel disease (IBD) patients treated with biologics were significantly less likely to undergo bowel resection when compared to those who never received biologics. This suggests that biologics may impact surgical rates in IBD patients.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology

Stefanos Bonovas et al.

Summary: The increased knowledge on the biological mechanisms underlying ulcerative colitis has led to the development of biologics and small molecule drugs, which have posed clinical dilemmas. This technical review provides clinical recommendations based on rigorous evaluation of evidence.

DIGESTIVE AND LIVER DISEASE (2022)

Add to Collection

Review Gastroenterology & Hepatology

Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials

Shomron Ben-Horin et al.

Summary: Initiating biologic treatment early in the course of Crohn's disease may yield better treatment outcomes, while disease duration does not significantly impact results in ulcerative colitis.

GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Long-term effectiveness and safety of ustekinumab in bio-naive and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study

Rogerio Serafim Parra et al.

Summary: This study retrospectively evaluated the effectiveness and safety of UST treatment in a large real-world cohort of Brazilian patients with refractory CD. The results showed that UST therapy was effective and safe for patients with biologically refractory CD, regardless of previous exposure to other biological agents.

BMC GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Prevalence, Indirect Costs, and Risk Factors for Work Disability in Patients with Crohn's Disease at a Tertiary Care Center in Rio de Janeiro

Renata de Sa Brito Froes et al.

Summary: In Rio de Janeiro, one-sixth of Crohn's disease patients are affected by work disability, with risk factors mainly related to disease duration and complications. As this disability impacts young patients after a relatively short period of illness, the socioeconomic burden of CD is expected to increase in the future due to the rising prevalence.

DIGESTIVE DISEASES AND SCIENCES (2021)

Add to Collection

Review Gastroenterology & Hepatology

Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts

Lester Tsai et al.

Summary: The patient-level risks of surgery in patients with ulcerative colitis and Crohn's disease have significantly decreased over time, with a 5-year cumulative risk of surgery of 7.0% in ulcerative colitis and 18.0% in Crohn's disease in contemporary cohorts. This decrease may be related to early detection and/or better treatment.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Management of Crohn Disease A Review

Kelly Cushing et al.

Summary: Crohn disease is a chronic gastrointestinal inflammatory disease that requires early and effective control of inflammation. Treatment options include medication, surgery, and vaccination for infection prevention. Physicians should consider disease severity, patient risk stratification, age, and other clinical factors when determining the best treatment strategy.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Review Dermatology

Socioeconomic impact of high-cost drugs in Brazilian dermatology. Legal and financial aspects, and impact on clinical practice

Renan Tironi Giglio de Oliveira et al.

Summary: The technological advancement of the pharmaceutical industry, combined with the expansion of immunopathogenesis knowledge, has changed the therapeutic options in dermatology. This study analyzed the current situation of high-cost drugs in the public health network, legal requirements for dermatological drugs, and the need for cost-effectiveness and public planning studies for incorporating new therapies. Legal issues remain a major factor in the demand for dermatological drugs, with psoriasis being the main disease involved in requiring medications through the judicial system in the state.

ANAIS BRASILEIROS DE DERMATOLOGIA (2021)

Add to Collection

Article Gastroenterology & Hepatology

Hospitalization and surgery rates in patients with inflammatory bowel disease in Brazil: a time-trend analysis

Flavia Goncalves Musauer Palacio et al.

Summary: There has been a decrease in hospitalization, surgery, and surgical-related lethality rates associated with IBD in Brazil, with uneven distribution in industrialized regions. The decentralization and improvements in public health services have contributed to these reductions.

BMC GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil

Ligia Yukie Sassaki et al.

Summary: The RISE BR study aimed to evaluate disease control, treatment patterns, and disease burden among patients with moderate-to-severe active inflammatory bowel disease in Brazil. Findings from the prospective follow-up phase showed that a significant proportion of patients achieved disease control, but it took considerable time to achieve this outcome in a real-world Brazilian setting.

WORLD JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme

Silvio Danese et al.

Summary: In the vedolizumab extended access programme, most patients showed persistence with treatment even after reducing dosing frequency to every 8 weeks, with low rates of relapse and re-escalation to the higher dosing frequency of every 4 weeks. The safety profile of vedolizumab remained consistent with previous reports, with infrequent adverse events reported.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Gastroenterology & Hepatology

The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation

K. T. Park et al.

INFLAMMATORY BOWEL DISEASES (2020)

Add to Collection

Review Gastroenterology & Hepatology

Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis

Shadi Hamdeh et al.

INFLAMMATORY BOWEL DISEASES (2020)

Add to Collection

Article Gastroenterology & Hepatology

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

Ryan C. Ungaro et al.

GASTROENTEROLOGY (2020)

Add to Collection

Review Gastroenterology & Hepatology

Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Bing Zhang et al.

JOURNAL OF CROHNS & COLITIS (2020)

Add to Collection

Letter Gastroenterology & Hepatology

Reduction of surgical rates in inflammatory bowel diseases biologic era: Similarities between Spain and Latin America

A. B. Quaresma et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)

Add to Collection

Article Economics

Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs

Ameur M. Manceur et al.

JOURNAL OF MEDICAL ECONOMICS (2020)

Add to Collection

Review Medicine, General & Internal

Early Intervention in Ulcerative Colitis: Ready for Prime Time?

Virginia Solitano et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Review Medicine, General & Internal

Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease

Edouard Louis

FRONTIERS IN MEDICINE (2020)

Add to Collection

Review Gastroenterology & Hepatology

The globalization of inflammatory bowel disease: the incidence and prevalence of inflammatory bowel disease in Brazil

Abel B. Quaresma et al.

CURRENT OPINION IN GASTROENTEROLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil

Rogerio S. Parra et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2019)

Add to Collection

Review Gastroenterology & Hepatology

Loss of response to scheduled infliximab therapy for Crohn's disease in adults: A systematic review and meta-analysis

Qi Wei Zhang et al.

JOURNAL OF DIGESTIVE DISEASES (2019)

Add to Collection

Review Gastroenterology & Hepatology

Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis

Siddharth Singh et al.

JOURNAL OF CROHNS & COLITIS (2018)

Add to Collection

Article Gastroenterology & Hepatology

Inflammatory bowel disease epidemiology in Sao Paulo State, Brazil

Rodrigo Galhardi Gasparini et al.

CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY (2018)

Add to Collection

Article Economics

The socio-economic impact of work disability due to inflammatory bowel disease in Brazil

Renata de S. B. Froes et al.

EUROPEAN JOURNAL OF HEALTH ECONOMICS (2018)

Add to Collection

Review Gastroenterology & Hepatology

Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease

Yun Qiu et al.

JOURNAL OF GASTROENTEROLOGY (2017)

Add to Collection

Article Gastroenterology & Hepatology

Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease

Joana Torres et al.

GASTROENTEROLOGY (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.